Bevacizumab in cervical cancer: a step forward for survival-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bevacizumab in cervical cancer: a step forward for survival

Published:2017-10 Issue:10103 Volume:390 Page:1626-1628
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Banerjee Susana

Publisher

Elsevier BV

Subject

General Medicine

Reference10 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240);Tewari;Lancet,2017

3. Improved survival with bevacizumab in advanced cervical cancer;Tewari;N Engl J Med,2014

4. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study;Long;J Clin Oncol,2005

5. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study;Bonomi;J Clin Oncol,1985

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SQLE—a promising prognostic biomarker in cervical cancer: implications for tumor malignant behavior, cholesterol synthesis, epithelial-mesenchymal transition, and immune infiltration;BMC Cancer;2024-09-11

2. Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy;BMC Women's Health;2024-01-31

3. A panel of seven immune-related genes can serve as a good predictive biomarker for cervical squamous cell carcinoma;Frontiers in Genetics;2022-11-02

4. Donor-acceptor structured photothermal COFs for enhanced starvation therapy;Chemical Engineering Journal;2022-08

5. Effect of Number of Retrieved Lymph Nodes on Prognosis in FIGO Stage IA1-IIA2 Cervical Cancer Patients Treated With Primary Radical Surgery;Clinical Medicine Insights: Oncology;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3